Cure8 news brief
The study reports blood protein patterns that may identify people at elevated risk of Crohn’s disease years before diagnosis, which could enable earlier monitoring or targeted prevention research. It also points to gut barrier and macrophage pathways as early disease-related biology.
Researchers (biomarkers, genetics, immune-pathways), clinicians interested in early detection/risk stratification, and adult patients/families following IBD prevention research.
A new multi-cohort study measured 178 plasma proteins and identified a 29-protein signature that predicted future Crohn’s disease (CD) diagnosis years before clinical onset, with strong performance across several independent cohorts (reported AUCs 0.85–1.0).
A separate preclinical signature was reported for ulcerative colitis with lower predictive performance. The CD signature featured mainly downregulated proteins tied to gut barrier integrity and macrophage function; these changes correlated with shorter time to diagnosis.
The authors also examined twins and found that genetic and shared environmental factors influenced the preclinical protein signature, suggesting part of the signal reflects inherited or shared exposures.
Results come from population cohorts and proteomic discovery/validation analyses; further clinical validation and careful consideration of how to act on risk predictions will be needed before use in routine care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The findings suggest blood DNA methylation changes may mark UC long before symptoms start; that could eventually enable earlier risk identification or research into preventing progression to symptomatic disease.
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
